ArticleBladder (San Francisco, Calif.)2025
Systemic ozone therapy improves the quality of life in patients with bladder pain syndrome.
Article in Bladder (San Francisco, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder pain syndrome (BPS), also known as interstitial cystitis, is a chronic condition characterized by pelvic pain and urinary symptoms that severely impair patients' quality of life (QoL). The current therapeutic options often yield suboptimal results, prompting interest in complementary treatments. Systemic ozone therapy, known for its anti-inflammatory, immunomodulatory, and analgesic effects, may represent a promising adjunctive treatment for BPS. Objective: This study aimed to evaluate the efficacy and safety of systemic ozone therapy in improving the self-perceived QoL in patients with BPS. Methods: The retrospective observational study included 40 patients diagnosed with BPS according to ESSIC criteria. All patients underwent systemic ozone therapy administered through hemotransfusion, following a standardized protocol. Outcomes were assessed using the Short Form (SF)-36 questionnaire for QoL and the Global Response Assessment (GRA) for subjective treatment efficacy. Statistical analyses evaluated changes in SF-36 domain scores and their correlation with GRA results. Results: Patients demonstrated significant improvement across all domains of the SF-36 questionnaire, with the most notable gains observed in physical functioning and mental health. The mean GRA score confirmed patient-perceived effectiveness, showing a strong positive correlation with SF-36 improvements (p<0.05). No adverse events or complications were found during the study. Conclusion: Systemic ozone therapy appears to be a safe and effective complementary treatment for BPS, significantly enhancing patients' QoL across multiple domains. While these findings are promising, randomized controlled trials are needed to validate the results and further explore underlying mechanisms, such as the role of ozone in modulating inflammatory and neural pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.